Search clinical trials for: ANTIBODY

Total 5226 results

Cancer Institute and Hospital, Chinese Academy...

Recruiting

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy (HN)

Head and Neck Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Healthy

China
Beijing Friendship Hospital

Not yet recruiting

L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

Lymphoma | Hemophagocytic Lymphohistiocytosis | PD-1 Antibody | Epstein-Barr Virus

China
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Seagen Inc.

Not yet recruiting

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

United States
AstraZeneca

Recruiting

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Hepatocellular Carcinoma | Biliary Tract Cancer

China, Spain, Korea, Republic of, Italy, United Kingdom, United States, Japan, Taiwan, Hong Kong
Fudan University

Recruiting

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma (RAPID)

High-Risk Localized Soft Tissue Sarcoma

China
The Second Affiliated Hospital of Chongqing Medical...
Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...

Not yet recruiting

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Chronic Hepatitis b | Anti-PD-1 Antibody | Peg-IFNα

China
The Second Affiliated Hospital of Chongqing Medical...
Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...

Not yet recruiting

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Chronic Hepatitis b | Anti-PD-1 Antibody

China
Bio-Thera Solutions
Sun Yat-sen University

Recruiting

BAT7104 Injection in Patients With Advanced Malignant Tumors.

Advanced Malignant Tumor

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors (IUNU-RC)

Non-clear Renal Cell Carcinoma

China
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (REPLENISH)

Polymyalgia Rheumatica

United States, Australia, Germany, Belgium, France, Spain, Italy, Lebanon, Switzerland, Japan, Israel, Denmark, Argentina, Netherlands, Colombia, Chile, Hungary, Poland, Turkey, Czechia, Brazil, South Africa, Mexico, Canada, United Kingdom
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Locally Advanced

China
ImmunOs Therapeutics AG
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Solid Tumor, Adult

Australia
Sinocelltech Ltd.

Not yet recruiting

Study on the Antibody Level Against SARS-CoV-2 （COVID-19）in Dazhu County in 2023 (COVID-19)

COVID-19

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Advanced or Metastatic Urothelium Cancer

China
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen...

Recruiting

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Metastatic Bladder Carcinoma | Urachal Adenocarcinoma | Locally Advanced Bladder Carcinoma | Malignant Renal Pelvis Neoplasm | Malignant Ureter Neoplasm | Malignant Urethral Neoplasm and other conditions

United States
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Shanghai Miracogen Inc.

Not yet recruiting

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Squamous Cell Carcinoma of the Head and Neck

China
OSE Immunotherapeutics

Recruiting

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Advanced Tumor

France, Belgium
Wuhan Union Hospital, China

Not yet recruiting

SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

Metastatic Colorectal Cancer

China
Hospital Universitari Vall d'Hebron Research Institute
Queen's University, Belfast; Cystic Fibrosis Foundation; Hospital Vall d'Hebron; European Cystic Fibrosis Society - Clinical Trial Network

Recruiting

COVID-19 ANtibody Responses in Cystic Fibrosis: CAR-CF (CAR-CF)

COVID-19 | Cystic Fibrosis

Spain
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.; Shanghai Junshi Bioscience Co., Ltd.

Recruiting

PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC (Escape)

Esophageal Squamous Cell Carcinoma Abdominal Stage 0

China
Insel Gruppe AG, University Hospital Bern
Swiss National Science Foundation; University of Bern

Recruiting

Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma (MACOCUC-01)

Advanced Urothelial Carcinoma

Switzerland
Hua Li

Recruiting

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

China
Byondis B.V.

Recruiting

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Lymphoma

Spain, United Kingdom, Netherlands, Italy
Emory University
National Cancer Institute (NCI); Xencor, Inc.

Recruiting

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Castration-Sensitive Prostate Carcinoma

United States
Alpine Immune Sciences, Inc.

Recruiting

An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases (RUBY-3)

Lupus Nephritis | Immunoglobulin A Nephropathy | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Membranous Nephropathy

United States, Australia, Korea, Republic of, Austria, Norway, Spain, United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)

Relapsed Refractory Multiple Myeloma (RRMM)

Canada, United States, Korea, Republic of, Israel, Taiwan, Spain, Australia, Brazil, France, United Kingdom, Poland, Singapore, Netherlands, Italy
Shanghai Kanda Biotechnology Co., Ltd.

Recruiting

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Melanoma

China
Institute of Hematology & Blood Diseases Hospital...
Henan Cancer Hospital; Beijing Children's Hospital; Tianjin Medical University... and other collaborators

Recruiting

TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Liver Cancer

United States
Tongji Hospital
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma (CCGLC-008)

Hepatocellular Carcinoma Non-resectable

China
ETOP IBCSG Partners Foundation
GlaxoSmithKline; Development Limited

Recruiting

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (RAISE)

SCLC,Extensive Stage | SLFN11-positive

Switzerland, France, Spain, Italy
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Kirby Institute

Not yet recruiting

The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset

Hepatitis C

Australia
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Stage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | Microsatellite Stable Colon Carcinoma | Stage IIB Colon Cancer AJCC v8 | Stage IIC Colon Cancer AJCC v8

United States
Cancer Hospital of Guangxi Medical University

Recruiting

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Sintilimab

China
Huabo Biopharm Co., Ltd.
First Affiliated Hospital Bengbu Medical College

Recruiting

A Study of HB0030 Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease

Crohn Disease

China
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals

Recruiting

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Lung Cancer

United States
Shanghai Zhongshan Hospital

Recruiting

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage HCC

Hepatocellular Carcinoma

China
EDDC (Experimental Drug Development Centre), A*STAR...
Parexel

Recruiting

A Study of EBC-129 in Advanced Solid Tumours

Advanced Solid Tumours

United States, Singapore
Chinese PLA General Hospital
Wuxi Sinotide New Drug Discovery Institutes

Recruiting

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Australasian Gastro-Intestinal Trials Group
Olivia Newton-John Cancer Research Institute

Recruiting

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Australia
Shanghai Miracogen Inc.

Recruiting

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

China
AstraZeneca

Recruiting

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)

NSCLC

China, United States, United Kingdom, Korea, Republic of, Italy, Hungary, Spain, Vietnam, France, Brazil, Canada, Japan, Taiwan, Germany, Austria, Turkey, India, Peru, Poland, Sweden, Bulgaria, Greece, Mexico, Denmark
AcadeMab Biomedical Inc.

Recruiting

Safety of AM-928 Infusion in Advanced Solid Tumors

Advanced Solid Tumor

Taiwan
Shanghai Celfuture Biotech Co., Ltd.

Not yet recruiting

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Colorectal Cancer

China
REGENXBIO Inc.

Recruiting

AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Boys With DMD

Duchenne Muscular Dystrophy

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Epstein-Barr Virus Infection | Infectious Mononucleosis | Herpesvirus

United States

Search clinical trials for: ANTIBODY

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations